Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MCRB 
Seres Therapeutics Inc (MCRB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: MCRB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16
1 Year Target Price $16
| 2 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -73.82% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 168.61M USD | Price to earnings Ratio - | 1Y Target Price 16 |
Price to earnings Ratio - | 1Y Target Price 16 | ||
Volume (30-day avg) 5 | Beta 0.2 | 52 Weeks Range 6.53 - 24.66 | Updated Date 10/17/2025 |
52 Weeks Range 6.53 - 24.66 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.79 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.57% | Return on Equity (TTM) -1556.28% |
Valuation
Trailing PE - | Forward PE 10.26 | Enterprise Value 226251152 | Price to Sales(TTM) 390.27 |
Enterprise Value 226251152 | Price to Sales(TTM) 390.27 | ||
Enterprise Value to Revenue 805.87 | Enterprise Value to EBITDA -2.07 | Shares Outstanding 8754570 | Shares Floating 6459472 |
Shares Outstanding 8754570 | Shares Floating 6459472 | ||
Percent Insiders 12.92 | Percent Institutions 26.25 |
Upturn AI SWOT
Seres Therapeutics Inc
Company Overview
History and Background
Seres Therapeutics Inc. was founded in 2010 and focuses on developing microbiome therapeutics. They aim to treat diseases by modulating the composition and function of the human microbiome. A key milestone was the FDA approval of VOWST, their oral microbiome therapeutic, in 2023.
Core Business Areas
- Microbiome Therapeutics: Developing and commercializing oral microbiome therapeutics for various diseases.
- SER-109 (VOWST): VOWST (fecal microbiota spores, live-brpb) is an FDA-approved oral microbiome therapeutic for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI.
Leadership and Structure
Eric Dube is the CEO. The company has a board of directors and operates with functional departments like R&D, commercial, and finance.
Top Products and Market Share
Key Offerings
- VOWST: VOWST is an oral microbiome therapeutic for preventing recurrent Clostridioides difficile infection (CDI). The US market for CDI treatment is estimated to be over $1 billion. VOWST competes with other CDI treatments, including Dificid (Merck), Zinplava (Merck), and fecal microbiota transplantation (FMT). Seres has first-mover advantage in this specific market segment approved by FDA. Peak sales estimated at $450M. Estimated market share of approximately 25% of CDI treatment.
Market Dynamics
Industry Overview
The microbiome therapeutics industry is an emerging field focused on treating diseases by altering the composition and function of the human microbiome. It's characterized by high growth potential but also significant regulatory and scientific hurdles.
Positioning
Seres Therapeutics is a leader in the microbiome therapeutics space, particularly in the prevention of recurrent CDI. Their competitive advantage lies in their FDA-approved product and established manufacturing capabilities.
Total Addressable Market (TAM)
The total addressable market for microbiome therapeutics is estimated to be in the billions of dollars. Seres is focused on capturing a significant portion of the CDI treatment market initially with opportunities for further expansion into other indications and therapeutic areas.
Upturn SWOT Analysis
Strengths
- FDA-approved product (VOWST)
- Strong scientific expertise in microbiome research
- First-mover advantage in recurrent CDI prevention
- Established manufacturing capabilities
Weaknesses
- Limited commercial infrastructure
- Reliance on a single product for revenue
- Potential for competition from other microbiome therapies
- High operating expenses
Opportunities
- Expansion into new indications beyond CDI
- Partnerships with larger pharmaceutical companies
- Development of next-generation microbiome therapeutics
- Geographic expansion into new markets
Threats
- Regulatory hurdles and clinical trial failures
- Competition from established pharmaceutical companies
- Uncertainty surrounding long-term efficacy of microbiome therapies
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- MRK
- RDHL
Competitive Landscape
Seres has a first-mover advantage in FDA-approved microbiome therapies for CDI. However, Merck (MRK) has established products in the CDI market. Redhill (RDHL) is also an indirect competitor. Seres faces the challenge of building a commercial infrastructure to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was minimal until VOWST's approval. Future growth will depend on VOWST sales and expansion into new indications.
Future Projections: Analyst estimates project significant revenue growth in the coming years as VOWST gains market share.
Recent Initiatives: Recent initiatives include the commercial launch of VOWST and ongoing research into new microbiome therapeutics.
Summary
Seres Therapeutics is an emerging player in the microbiome therapeutics space, driven by its FDA-approved product, VOWST. Its success is tied to the successful commercialization of VOWST and expansion into new indications. However, it faces challenges related to commercial infrastructure and competition, especially as larger pharma companies develop their own therapies. While innovative, Seres needs to manage its finances carefully and prove the long-term value of its approach.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Seres Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2015-06-26 | Co-CEO, Co-President & Chief Legal Officer Mr. Thomas J. DesRosier Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 103 | |
Full time employees 103 | |||
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.